Transplantation Proceedings
Volume 40, Issue 1 , Pages 16-21 , January 2008

Effects of Losartan and Enalapril on High-Sensitivity C-Reactive Protein and Total Antioxidant in Renal Transplant Recipients With Renin-Angiotensin System Polymorphisms

  • H. Argani

      Affiliations

    • Nephrology Department, Shaheed Beheshti Medical University, Tabriz, Iran
    • ,
  • A. Ghorbanihaghjo

      Affiliations

    • Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.
    • ,
  • M. Aghaeishahsavari

      Affiliations

    • Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.
    • Corresponding Author InformationAddress reprint requests to Mohammad Aghaeishahsavari, Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.
    • ,
  • M. Noroozianavval

      Affiliations

    • Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.
    • ,
  • N. Rashtchizadeh

      Affiliations

    • Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.
    • ,
  • P. Veisi

      Affiliations

    • Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.
    • ,
  • J. Safa

      Affiliations

    • Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.
    • ,
  • S. Abediazar

      Affiliations

    • Drug Applied Research Center (DARC), Biotechnology Research Center, Tabriz Medical University, Tabriz, Iran.

References 

  1. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121
  2. Tan K, Chou WS, Wong Y, et al. Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2002;25:1254
  3. Sezer S, Uyar M, Akcay A, et al. Endothelial nitric oxide synthase and angiotensin II type I receptor gene polymorphisms can influence chronic inflammatory state in renal transplant patients. Transplant Proc. 2005;37:776
  4. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006;24:33
  5. Vural A, Yilmaz MI, Caglar K, et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol. 2005;25:250
  6. Parildar M, Parildar Z, Oran I, et al. Nitric oxide and oxidative stress in atherosclerotic renovascular hypertension: effect of endovascular treatment. J Vasc Interv Radiol. 2003;14:887
  7. Steinerova A, Racek J, Stozicky F, et al. Antibodies against oxidized LDL—theory and clinical use. Physiol Res. 2001;50:131
  8. Boratynska M, Boratynski J, Klinger M, et al. Lipid peroxidation and cytokines in chronic allograft failure: influence of nonimmunological risk factors. Transplant Proc. 2000;32:1384
  9. Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlated, and outcomes: a 20-year clinical experience. Am J Kidney Dis. 1994;24:622
  10. Akcay A, Ozdemir FN, Atac FB, et al. Angiotensin-converting enzyme genotype is a predictive factor in the peak panel-reactive antibody response. Transplant Proc. 2004;36:35
  11. Yavuz D, Koc M, Toprak A, et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst. 2003;4:197
  12. Pechter U, Aunapuu M, Riispere Z, et al. Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. Nephron Exp Nephrol. 2004;97:33
  13. Bayorh MA, Ganafa AA, Eatman D, et al. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens. 2005;18:1496
  14. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol. 2001;37:1461
  15. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol. 2003;284:863
  16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215
  17. Frishberg Y, Becker-Cohen R, Halle D, et al. Genetic polymorphisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Kidney Int. 1998;54:1843
  18. Ohno T, Kawazu S, Tomono S. Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism. 1996;45:218
  19. Mitrovic V, Klein HH, Krekel N, et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol. 2005;94:336
  20. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab. 2003;88:4496
  21. Tikiz C, Utuk O, Pirildar T, et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long-term rheumatoid arthritis. J Rheumatol. 2005;32:2095
  22. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol. 2003;482:95
  23. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586
  24. Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res. 2002;90:770
  25. Proudfoot JM, Croft KD, Puddey IB, et al. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther. 2003;305:846
  26. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103
  27. Perez Fernandez R, Martin Mateo MC, De Vega L, et al. Antioxidant enzyme determination and a study of lipid peroxidation in renal transplantation. Ren Fail. 2002;24:353
  28. Tkaczewski W, Kedziora J, Buczynski A, et al. [Effect of captopril on superoxide dismutase (SOD-1) activity and malondialdehyde (MDA) level in blood platelets in patients with arterial hypertension]. Kardiol Pol. 1989;32:138
  29. Tepel M, Echelmeyer M, Orie NN, et al. Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int. 2000;58:867
  30. Wang L, Zou YL, Lin SG. Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril. Di Yi Jun Yi Da Xue Bao. 2005;25:691

 This work is part of a project supported by a grant from the Drug Applied Research Center (DARC) and Vice-Chancellor for Research of Tabriz Medical University.

PII: S0041-1345(07)01382-6

doi: 10.1016/j.transproceed.2007.11.033

Transplantation Proceedings
Volume 40, Issue 1 , Pages 16-21 , January 2008

Article Tools